BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, August 6th. Investors of record on Friday, August 16th will be paid a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) posted its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.08. The biotechnology company had revenue of $191.66 million for the quarter, compared to analyst estimates of $196.37 million. BIO-TECHNE had a return on equity of 13.20% and a net margin of 13.45%. BIO-TECHNE's revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.34 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 brokers have issued 12 month price targets for BIO-TECHNE's stock. Their predictions range from $165.00 to $270.00. On average, they expect BIO-TECHNE's stock price to reach $206.80 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

News articles about TECH stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of -2.6 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 799,800 shares, an increase of 8.1% from the August 15th total of 739,700 shares. Based on an average daily volume of 166,700 shares, the days-to-cover ratio is currently 4.8 days. Currently, 2.1% of the company's stock are short sold. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO) and Iovance Biotherapeutics (IOVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Amgen (AMGN), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH) and Illumina (ILMN).

BIO-TECHNE's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Riverbridge Partners LLC (1.05%), Pacer Advisors Inc. (0.04%), State of Alaska Department of Revenue (0.02%), Crossmark Global Holdings Inc. (0.01%), Diversified Trust Co (0.00%) and Clarus Wealth Advisors (0.00%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Pacer Advisors Inc. and Crossmark Global Holdings Inc.. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Clarus Wealth Advisors and Diversified Trust Co. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $200.95.

BIO-TECHNE has a market capitalization of $7.61 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]